Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Integra Lifesciences Holdings (IART) Share-based Compensation (2016 - 2025)

Historic Share-based Compensation for Integra Lifesciences Holdings (IART) over the last 17 years, with Q3 2025 value amounting to $5.6 million.

  • Integra Lifesciences Holdings' Share-based Compensation rose 2733.91% to $5.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $19.9 million, marking a year-over-year decrease of 1355.9%. This contributed to the annual value of $24.4 million for FY2024, which is 2101.97% up from last year.
  • Per Integra Lifesciences Holdings' latest filing, its Share-based Compensation stood at $5.6 million for Q3 2025, which was up 2733.91% from $5.3 million recorded in Q2 2025.
  • Integra Lifesciences Holdings' Share-based Compensation's 5-year high stood at $15.7 million during Q2 2021, with a 5-year trough of $1.9 million in Q1 2025.
  • Moreover, its 5-year median value for Share-based Compensation was $5.8 million (2023), whereas its average is $6.4 million.
  • Its Share-based Compensation has fluctuated over the past 5 years, first surged by 20353.83% in 2021, then tumbled by 6660.12% in 2025.
  • Quarter analysis of 5 years shows Integra Lifesciences Holdings' Share-based Compensation stood at $6.4 million in 2021, then fell by 10.9% to $5.7 million in 2022, then grew by 1.08% to $5.8 million in 2023, then rose by 23.46% to $7.2 million in 2024, then fell by 21.98% to $5.6 million in 2025.
  • Its Share-based Compensation stands at $5.6 million for Q3 2025, versus $5.3 million for Q2 2025 and $1.9 million for Q1 2025.